Ani Pharmaceuticals (ANIP) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to 0.36.
- Ani Pharmaceuticals' Equity Ratio fell 948.62% to 0.36 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.36, marking a year-over-year decrease of 948.62%. This contributed to the annual value of 0.31 for FY2024, which is 4467.83% down from last year.
- Latest data reveals that Ani Pharmaceuticals reported Equity Ratio of 0.36 as of Q3 2025, which was down 948.62% from 0.33 recorded in Q2 2025.
- In the past 5 years, Ani Pharmaceuticals' Equity Ratio registered a high of 0.57 during Q4 2023, and its lowest value of 0.31 during Q4 2024.
- Its 5-year average for Equity Ratio is 0.45, with a median of 0.46 in 2022.
- Its Equity Ratio has fluctuated over the past 5 years, first surged by 3281.99% in 2022, then plummeted by 4467.83% in 2024.
- Over the past 5 years, Ani Pharmaceuticals' Equity Ratio (Quarter) stood at 0.5 in 2021, then grew by 5.72% to 0.53 in 2022, then grew by 6.97% to 0.57 in 2023, then tumbled by 44.68% to 0.31 in 2024, then increased by 14.23% to 0.36 in 2025.
- Its Equity Ratio stands at 0.36 for Q3 2025, versus 0.33 for Q2 2025 and 0.32 for Q1 2025.